Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Background: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
[PDF][PDF] Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - academia.edu
BACKGROUND: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
[HTML][HTML] Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - ncbi.nlm.nih.gov
BACKGROUND: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> A better understanding of the
factors that contribute to heterogeneous outcomes and lifetime disease burden in …
factors that contribute to heterogeneous outcomes and lifetime disease burden in …
[PDF][PDF] Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - pure.eur.nl
BACKGROUND: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)
H CY, SM Day, EA Ashley, M Michels, AC Pereira… - CIRCULATION, 2018 - flore.unifi.it
Data on 4591 patients with HCM (2763 genotyped) followed up for a mean of 5.4±6.9 years
(24791 patient-years; median, 2.9 years; interquartile range, 0.3–7.9 years) were analyzed …
(24791 patient-years; median, 2.9 years; interquartile range, 0.3–7.9 years) were analyzed …
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
CY Ho, SM Day, EA Ashley, M Michels… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Background A better understanding of the factors that contribute to heterogeneous outcomes
and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to …
and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to …
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
CY HO, SM DAY, EA ASHLEY, M MICHELS… - …, 2018 - observatorio.fm.usp.br
Background: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - Am Heart Assoc
BACKGROUND: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
[PDF][PDF] Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
CY Ho, SM Day, EA Ashley, M Michels, AC Pereira… - Circulation, 2018 - swissdnalysis.ch
BACKGROUND: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …